Not Yet RecruitingPhase 4ACTRN12611000589987

Randomised placebo controlled trial of inhaled corticosteroids for treatment of acute and chronic cough in children.

Is a two week course of inhaled corticosteroids efficacious as primary treatment of cough in children, compared to standard therapy?


Sponsor

Prof Anne Chang

Enrollment

161 participants

Start Date

Jun 8, 2011

Study Type

Interventional

Conditions

Summary

This study will help us answer the question: Should children with acute or chronic cough be given inhaled corticosteroids to promote faster recovery and improve ability for children to return to their normal daily routines? This study will also look at what viruses may be contributing to cough in children and how cough impacts on the quality of life of children and their families.


Eligibility

Sex: Both males and femalesMin Age: 2 YearssMax Age: 16 Yearss

Inclusion Criteria1

  • Children with acute or chronic cough.

Exclusion Criteria5

  • Children who have received oral or inhaled corticosteroids in the week prior to presentation.
  • Children who are unable to tolerate inhaled corticosteroids or spacer.
  • Children with cerebral palsy or severe neuro-developmental abnormality.
  • Children with physician-confirmed underlying chronic respiratory illness.
  • Children who are immunocompromised.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Participants will be randomised to receive either inhaled corticosteroids or placebo. Participants allocated to the intervention group will receive 250 micrograms fluticasone propionate twice daily fo

Participants will be randomised to receive either inhaled corticosteroids or placebo. Participants allocated to the intervention group will receive 250 micrograms fluticasone propionate twice daily for two weeks, delivered via metered dose inhaler and spacer (with or without mask, depending on age and technique).


Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12611000589987